The Somatostatin Analog 188Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

Carol A. Nelson1,2, Michael T. Azure3, Christopher T. Adams2, and Kurt R. Zinn3

1Translational Medicine Consulting, Westford, Massachusetts; 2Department of Research and Development, Andarix Pharmaceuticals, Watertown, Massachusetts; and 3Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama

P2045 is a peptide analog of somatostatin with picomolar affinity for the somatostatin receptor subtype 2 (SSTR2) upregulated in some pancreatic tumors. Studies were conducted in rat AR42J pancreatic tumor xenograft mice to determine whether 188Re-P2045 could inhibit the growth of pancreatic cancer in an animal model. Methods: 188Re-P2045 was intravenously administered every 3 d for 16 d to nude mice with AR42J tumor xenografts that were approximately 20 mm³ at study initiation. Tumor volumes were recorded throughout the dosing period. At necropsy, all tissues were assessed for levels of radioactivity and evaluated for histologic abnormalities. Clinical chemistry and hematology parameters were determined from terminal blood samples. The affinity of nonradioactive 185/187Re-P2045 for somatostatin receptors was compared in human NCI-H69 and rat AR42J tumor cell membranes expressing predominantly SSTR2. Results: In the 1.85- and 5.55-MBq groups, tumor growth was inhibited in a dose-dependent fashion. In the 11.1-MBq group, tumor growth was completely inhibited throughout the dosing period and for 12 d after the last administered dose. The radioactivity level in tumors 4 h after injection was 10 percentage injected dose per gram, for 12 d after the last administered dose. The radioactivity level in tumors 4 h after injection was 10 percentage injected dose per gram, for 12 d after the last administered dose. The expression of SSTR2 has also been reported in tumor neovasculature but not in normal vasculature (4). Tumor expression of SSTR provides the basis for detection and staging of disease by the administration of SSTA coupled to γ-emitting radioisotopes followed by scintigraphy (5). For example, pentreotide ([diethylaminoethyl] pentaacetic acid] octreotide) labeled with 111In is approved for the detection of neuroendocrine tumors (6), and depreotide labeled with 99mTc was previously approved for the detection of lung cancer (7). Cytotoxic moieties have been coupled to peptides and antibodies and thereby targeted to upregulated receptors on tumors (1, 8). The peptide approach has some advantages. Peptides are smaller and can diffuse more readily into tumor tissue. Furthermore, peptides are less likely to produce an immune response and can be transported into tumor cells by receptor-mediated endocytosis. They are also cleared rapidly from the circulation, resulting in decreased whole-body exposure. As such, SSTA labeled with cytotoxic isotopes have been used to deliver radiotherapeutics to tumors overexpressing SSTR (2, 9). For example, clinical trials have been conducted with the SSTA 90Y-DOTATOC and 177Lu-DOTATATE for the treatment of neuroendocrine tumors (10). Another SSTA, P2045 labeled with 188Re, was evaluated in a clinical trial for lung cancer (9) in which there was a good correlation between the visualization of lung tumors with 99mTc-P2045 and 188Re-P2045 uptake (11). Neuroendocrine tumors of the pancreas, gut, and lung overexpress SSTR (2,13), and for this reason 188Re-P2045 may be an effective therapy for this class of tumors. The studies herein describe proof of concept for 188Re-P2045 therapy in the AR42J rat pancreatic tumor xenograft nude mouse.

**MATERIALS AND METHODS**

188Re-P2045 and Control Preparation

A lyophilized mix of P2045 peptide trifluoroacetate (53 μg of free peptide), sodium α-glucoheptapeptide dihydrate (25 mg), edetate disodium hydride (100 μg), and SnCl₂ (850 μg) was reconstituted with 1.1 GBq of Sodium Perrhenate 188Re from a generator (Oak Ridge National Laboratories) and boiled for 15 min. Lyophilized gentisic acid (20 mg) and ascorbic acid (10 mg) were reconstituted with saline and added to the cooled 188Re-P2045 solution. Peptide control saline was added in place of 188Re. Vehicle was decayed generator eluate.

J Nuc Med 2014; 55:1–6
DOI: 10.2967/jnumed.114.140780
Quality Analysis of $^{188}$Re-P2045

$^{188}$Re-P2045 was determined using instant thin-layer chromatography silica gel (Gelman) developed in saturated saline, 1:1 methanol:1.0 M ammonium acetate, and methyl ethyl ketone.

For high-performance liquid chromatography (HPLC), $^{188}$Re-P2045 was eluted on a linear gradient 50%–54% A to B over 32 min on a Zorbax 300SB reversed-phase column (880995–902; Rockland Technologies). Mobile phase A was 0.1% trifluoroacetic acid in water. Mobile phase B was 0.1% trifluoroacetic acid in 90/10 methanol/water.

$^{88}$Y-DOTATOC Preparation

$^{88}$YCl$_3$ (555 MBq; NEN) in 12 µL of 0.05 M HCl was added to 10 µg of DOTATOC (Diadite) in 1.0 mL of saline with 0.5 µL of 1 mM YCl$_3$. The vial was boiled for 25 min, cooled to room temperature, and passed through a QMA Light Sep-Pak column (Waters). The column was rinsed with 1.0 mL of ammonium acetate and 2.0 mL of phosphate-buffered saline and eluted with a solution of 50% ethanol. Solvent was removed by vacuum, and $^{88}$Y-DOTATOC was reconstituted with saline.

$^{185/187}$Re-P2045 Preparation

Nonradioactive $^{185/187}$Re-P2045 was prepared by reacting peptide with a 1.5-fold molar excess of Bu$_4$NReOCl$_4$ in anhydrous dimethylformamide at room temperature ($\theta$). Products were isolated by reversed-phase HPLC.

Binding Studies

NCI-H69 or AR42J cell membranes were incubated with $^{125}$I-(Tyr11)-SST14 (NEN) at 37°C (pH 7.4) in the presence of test peptides as described previously ($\theta$). Membrane-bound $^{125}$I-SST was isolated by filtration. Nonspecific binding was determined in the presence of excess SST14 (10 µM; Sigma). The inhibition of specific binding was calculated at 6 concentrations of test peptide (0.01–100 nM) and plotted using a Stineman function (Kaleidagraph 4.5; Synergy Software) from which the IC$_{50}$ values were calculated. (IC$_{50}$ value is defined as the concentration of agent required to inhibit the specific binding of $^{125}$I-SST14 by 50%.)

Animal Model

University of Alabama at Birmingham’s institutional animal care and use committee approved all animal studies. Washed cells were mixed with Matrigel (Collaborative Biochemical Products) and injected subcutaneously into outbred athymic nude mice Crl:NU/Nu-nuBR (Charles River). Resulting tumor xenografts were minced, collected without anticoagulant. All tissues were examined during necropsy for gross abnormalities. Tissues were fixed in 10% formalin, embedded in paraffin, sectioned at 5 µm, and stained with hematoxylin and eosin. A single tumor section from each animal was used to determine

**Table 1**

Design of Repeated-Dose Study in AR42J Tumor Mice

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of animals per group</th>
<th>No. of doses</th>
<th>Treatment</th>
<th>Route</th>
<th>End time</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>10</td>
<td>6</td>
<td>Decayed generator eluate</td>
<td>Intravenous</td>
<td>16 d</td>
</tr>
<tr>
<td>2</td>
<td>10</td>
<td>6</td>
<td>530 ng of nonradio labeled P2045</td>
<td>Intravenous</td>
<td>16 d</td>
</tr>
<tr>
<td>3</td>
<td>10</td>
<td>6</td>
<td>1.85 MBq of $^{188}$Re-P2045</td>
<td>Intravenous</td>
<td>16 d</td>
</tr>
<tr>
<td>4</td>
<td>10</td>
<td>6</td>
<td>5.55 MBq of $^{188}$Re-P2045</td>
<td>Intravenous</td>
<td>16 d</td>
</tr>
<tr>
<td>5</td>
<td>10</td>
<td>6</td>
<td>11.1 MBq of $^{188}$Re-P2045</td>
<td>Intravenous</td>
<td>28 d</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>1</td>
<td>22.2 MBq of $^{88}$Y-DOTATOC</td>
<td>Intraperitoneal</td>
<td>16 d</td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>1</td>
<td>9.25 MBq of $^{188}$Re-P2045</td>
<td>Intravenous</td>
<td>4 h</td>
</tr>
<tr>
<td>8</td>
<td>5</td>
<td>1</td>
<td>9.25 MBq of $^{188}$Re-P2045</td>
<td>Intravenous</td>
<td>24 h</td>
</tr>
<tr>
<td>9</td>
<td>5</td>
<td>1</td>
<td>11.1 MBq of $^{88}$Y-DOTATOC</td>
<td>Intravenous</td>
<td>4 h</td>
</tr>
<tr>
<td>10</td>
<td>5</td>
<td>1</td>
<td>11.1 MBq of $^{88}$Y-DOTATOC</td>
<td>Intravenous</td>
<td>24 h</td>
</tr>
</tbody>
</table>
the area of necrotic tissue with Image-Pro Plus software (version 3.0) with a Hitachi single-chip camera mounted on an Olympus AH-1 microscope. Calibration was performed using neutral-buffered saline–traceable stage micrometers. A board-certified pathologist graded all tissue samples in a masked fashion.

**Statistical Analysis**

Tumor volumes were compared using ANOVA, followed by Dunnett test to compare each treatment group with the vehicle control group (Graphpad Instat, version 3; GraphPad Software).

**RESULTS**

**Radiochemical Purity of $^{188}$Re-P2045**

The radiochemical purity of the $^{188}$Re-P2045 determined from instant thin-layer chromatography and HPLC was greater than 89% for all $^{188}$Re-P2045 solutions used in the study (Supplemental Table 1; supplemental materials are available at http://jnm.snmjournals.org).

**Purity of $^{185/187}$Re-P2045**

The purity of $^{185/187}$Re-P2045 was greater than 95% by HPLC.

**Binding Studies**

P2045 and its nonradioactive oxo-rhenium complex, $^{185/187}$Re-P2045, bound with picomolar affinity to SSTR in the rat AR42J and human NCI-H69 tumor cell membranes (Table 2). The IC$_{50}$ in AR42J and NCI-H69 membranes was 0.43 and 0.2 nM, respectively. The IC$_{50}$ of the nonradioactive rhenium complex was 0.50 nM in AR42J and 0.23 nM in NCI-H69 cell membranes. The standard errors were less than 40% of the mean for all IC$_{50}$ values. The IC$_{50}$ values for P2045 peptide and $^{185/187}$Re-P2045 are similar to that of native SST (0.2 nM) in NCI-H69 human small cell lung cancer membranes.

**Inhibition of Tumor Growth**

The mean tumor volumes are presented in Supplemental Table 2 and Figure 1. The tumor growth in the P2045 peptide control mice was not significantly different from the decayed eluate controls. However, there was a dose-related delay in tumor growth in the $^{188}$Re-P2045–treated mice relative to the generator eluate controls. Statistically significant differences in tumor volumes were observed 6 d after the first injection when the tumors in the high-dose $^{188}$Re-P2045 group were smaller than those in the decayed eluate control group ($P < 0.05$). Nine days after the first injection, all $^{188}$Re-P2045 treatment groups showed a significant decrease in tumor growth ($P < 0.05$, 0.05, and 0.01 in the low-, medium-, and high-dose groups, respectively). Thirteen days after the first injection, the tumor volumes in the low-, medium-, and high-dose groups were 91, 44, and 13 mm$^3$ ($P < 0.01$), respectively, whereas the tumor volume in the eluate control group was 318 mm$^3$. In the high-dose group, there was slight regression in mean tumor volume observed over the dosing period, although this was not statistically significant. Tumor growth in the $^{89}$Y-DOTATOC–treated mice was also inhibited.

All mice were sacrificed on study day 16 or earlier except for the high-dose $^{188}$Re group. The mice in this group were followed for an additional 12 d with no dosing to determine the duration of the therapeutic effect. The mean tumor volume did not increase significantly until 12 d after the last dose (study day 28).

**Biodistribution**

The biodistribution of $^{188}$Re-P2045 and $^{89}$Y-DOTATOC is shown in Figure 2. At 4 h after injection, the levels of $^{188}$Re-P2045 in the tumor were 9.8 %ID/g. At 24 h, the tumor retained roughly two thirds of the radioactivity (6.6 %ID/g) observed at 4 h. In contrast, $^{188}$Re-P2045 cleared rapidly from the blood such that the tumor-to-blood ratios increased from 83 to 289 at 4 and 24 h, respectively (Supplemental Table 3). The highest radioactivity in the $^{188}$Re-P2045 groups was observed in the tumor. There was roughly twice as much radioactivity in the tumors as in the kidneys at 4 h after injection. In contrast, the level of $^{89}$Y-DOTATOC in the kidneys was higher than the level in the tumors.

Scintigraphy of 3 representative AR42J mice after an intravenous injection of $^{188}$Re-P2045 (9.25 MBq of $^{188}$Re-P2045) is shown in Figure 3. Three minutes after injection, the bladder was visible along with the core blood volume. Eight hours after injection, the tumor and kidneys were visible and by 24 h after injection the radioactivity was predominantly located in the tumor. The biodistribution of $^{188}$Re-P2045 in the tumor, blood, kidneys, and gut after multiple doses of $^{188}$Re-P2045 in the therapeutic arm of the study is shown in Table 3. The radioactivity in the tumor and tissues of mice receiving multiple doses of $^{188}$Re-P2045...
was not different from mice that received a single dose. The tumor uptake of $^{188}$Re-P2045 in study groups receiving 6 doses of $^{188}$Re-P2045 over 16 d was 10.2, 10.3, and 10.4 %ID/g in the low-, medium-, and high-dose groups, respectively. In all $^{188}$Re-P2045 groups, the radioactivity in the tumor was roughly 2 times higher than that in the kidneys and there were relatively small amounts retained in the gut.

Clinical Observations, Necropsy, Hematology, and Histopathology

$^{188}$Re-P2045 was well tolerated, and adverse clinical findings were not observed in any of the $^{188}$Re-P2045 study groups. There were no significant differences in mean animal weights, and the organ–to–body weight ratios remained in the range of historic data for healthy untreated mice (J5). No macroscopic abnormalities were observed during necropsy. No abnormal histopathology was noted in any tissues. As expected, undifferentiated tumor cells typical of the AR42J tumor were observed in all tumor sections, and there was no significant difference in the percentage of necrosis in any of the groups tested.

The clinical chemistry and hematology results are shown in Supplemental Table 3. The percentage of neutrophils in the $^{188}$Re-P2045 treatment groups were elevated severalfold, compared with the vehicle control group ($P < 0.01$). All other hematologic parameters were unchanged in the $^{188}$Re-P2045 treatment groups. In addition, the clinical chemistry biomarkers of renal function, blood urea nitrogen, and creatinine were unchanged in the $^{188}$Re-P2045 groups, compared with vehicle controls.

DISCUSSION

The current study demonstrates that $^{188}$Re-P2045 inhibits tumor growth in a model of pancreatic cancer. Two controls were used, 1 with free peptide and 1 with decayed generator eluate. There was a 22-fold increase in tumor growth by study day 16 in the mock eluate control group, and free peptide did not inhibit tumor growth. In comparison, the intravenous administration of $^{188}$Re-P2045 once every 3 d for 16 d resulted in a dose-related delay in tumor growth in the low- and mid-dose groups of 2- and 5-fold, respectively, compared with the first day of dosing. In the high-dose group, tumor growth was completely inhibited by $^{188}$Re-P2045 treatment. In fact, the mean tumor volume decreased steadily in the high-dose group over the course of treatment, although this decrease was not statistically significant. After the last dose of $^{188}$Re-P2045 was administered, tumor volumes in the high-dose group were measured over time with no additional dosing to assess the duration of the therapeutic effect. An increase in mean tumor volume was not observed until 12 d after the last dose was given, suggesting a long-lived therapeutic affect.

$^{188}$Re-P2045 was safe and well tolerated in all dose groups. No mortality or abnormal behavior, body weights, organ weights, or histology were observed in the $^{188}$Re-P2045 groups. Clinical chemistries were not different between $^{188}$Re-P2045–treated and vehicle-treated mice. A small but statistically significant increase in the percentage of circulating neutrophils was observed in all $^{188}$Re-P2045 treatment groups, possibly due to the activation of neutrophils in response to tumor cell apoptosis induced by ionizing radiation (J6).

$^{188}$Re-P2045 cleared rapidly from the blood and nontumor tissues and paralleled that of the blood clearance. In contrast, $^{188}$Re-P2045
cleared slowly from the tumor. The tumor-to-blood ratios were 83 and 289 at 4 and 24 h after a single dose. Gamma camera images and biodistribution studies demonstrated that most of the radioactivity was localized within the tumor xenograft. This result was confirmed in biodistribution studies. It is likely that receptor-ligand internalization is responsible for the delayed clearance of 188Re-P2045 from tumors (17,18). Although difficult to demonstrate in vivo, 188Re-P2045 is internalized after binding to human SSTR2 transfected into HEK-293 cells in vitro (17,19). It follows that P2045 is likely an SSTR agonist because only agonists are internalized (20).

G-protein–coupled receptors desensitize after prolonged exposure to agonists (21). Downregulation of SSTR has been observed in tumors exposed to SSTAs (22). Receptor desensitization results in a decreased number of receptors on the cell surface and may cause a decrease in 188Re-P2045 in tumors after repeated doses. To test this possibility, the radioactivity in the tumors of animals receiving a single dose of 188Re-P2045 was compared with tumors in the study animals that had received multiple doses of 188Re-P2045. The radioactivity in all tumors was roughly the same, suggesting that either desensitization did not occur at the doses administered or that the SSTR had resensitized during the 3-d dosing interval (23).

The exposure of kidneys to peptide radiotherapeutic agents is a dose-limiting factor in clinical studies (24). Radiolabeled peptides are mainly excreted via the kidneys and are partly reabsorbed in the renal proximal tubules leading to kidney retention. High radiation dose to the kidneys can lead to kidney failure; therefore, it is important to minimize the kidney retention of radiotherapeutic peptides (25). Structural modifications to the chelating portion of depreotide were made to produce a library of peptides with low kidney and high tumor retention. P2045 was chosen from this library for its favorable biodistribution characteristics in SSTR2-expressing murine xenograft models. The murine kidney retention of radiolabeled P2045 was roughly 25-fold lower and the tumor uptake 4-fold higher than that of depreotide (14). Importantly, markers of renal function, including blood urea nitrogen and creatinine, were normal in the 188Re-P2045 treatment groups. Furthermore, kidney histopathology was normal in the 188Re-P2045 treatment groups. The high tumor retention coupled with low kidney exposure makes 188Re-P2045 a promising cancer therapeutic candidate.

The AR42J tumor xenograft model was chosen for its SSTR density (14). However, the AR42J tumor originates from rat pancreatic tissue. To determine whether this model was predictive of 188Re-P2045 binding to human SSTR, the binding affinity of 185/187Re-P2045 for SSTR was compared in membranes prepared from rat AR42J and human NCI-H69 tumor cells expressing predominantly SSTR2. Because the IC50 values were similar (3), the AR42J model was considered representative of human SSTR2-expressing tumors.

177Lu-DOTATATE is considered the current gold standard for the treatment of SSTR2-expressing tumors (26). Although we conducted no 177Lu-DOTATATE studies in our laboratory, the important comparators are published (26,27). The binding affinity of 177Lu-DOTATATE for human SSTR2-transfected cell membranes was reported to be 1.5 ± 0.4 SEM nM (27), and the binding affinity of 177Lu-DOTATATE for rat SSTR2 expressed in AR42J membranes was 0.21–0.23 nM (28). In contrast, 185/187Re-P2045 bound more avidly to human H69 SSTR2 (0.23 ± 0.1 nM, Table 2) and less avidly to rat SSTR2 expressed in AR42J tumor membranes (0.43 ± 0.19, Table 2). These studies suggest that 188Re-P2045 binds with approximately 7-fold-higher avidity to human SSTR2 and with 2-fold-lower avidity to rat SSTR than 177Lu-DOTATATE. It follows that the AR42J tumor model might favor higher tumor levels of 177Lu-DOTATATE but clinical studies might favor tumor uptake of 188Re-P2045. Levels of radioactivity in the AR42J tumor were similar for both agents (Fig. 2) (26).

The physical characteristics of 188Re are superior to those of 177Lu. 188Re is inexpensively produced from an on-site 188W/188Re generator (29,30). The generator is shipped to hospitals where its shelf-life is several months, and the specific activity of the eluted 188Re is greater than 25.9 MBq/mL (30). Additionally, 188Re has a decay half-life of 17 h that is ideal for radiotherapy because its radioactive decay parallels the biologic clearance of 188Re-P2045. Furthermore, the same 188Re chelator can be used to complex 99mTc to P2045 for imaging (5), and both P2045-chelated products distribute similarly in the body (14). Because different SSTAs have different signature affinities for each of the SSTR subtypes (2), the ideal scenario is to use the same peptide for diagnosis as for radiotherapy. In contrast, 177Lu must be shipped on-demand from a facility with a cyclotron and has a half-life of 6.65 d (26).

**CONCLUSION**

This study demonstrates that 188Re-P2045 inhibited tumor growth in a model of SSTR2-expressing pancreatic cancer in a dose-related fashion. The agent was well tolerated in all treatment groups and cleared rapidly from the blood and nontarget tissues. Levels of 188Re-P2045 were low in the kidneys, and parameters of kidney...
function were normal. Levels of $^{188}$Re-P2045 were high in the tumor, and levels were not diminished by multiple doses. Collectively, these data indicate that $^{188}$Re-P2045 is a promising therapeutic candidate for the treatment of cancers expressing SSTR2. $^{188}$Re-P2045, also known as Tozaride (Andarix Pharmaceuticals), is currently in active development and has recently received orphan drug designation in the United States for small cell lung and pancreatic cancer.

**DISCLOSURE**

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734. Christopher P. Adams owns and Carol A. Nelson and Christopher P. Adams own stock options in Andarix Pharmaceuticals, a company developing $^{188}$Re-P2045 for clinical use. No other potential conflict of interest relevant to this article was reported.

**ACKNOWLEDGMENTS**

This publication is dedicated to Dr. Michael T. Azure who died in 2013. He is greatly missed by his friends and colleagues. We thank Dr. Trenton Schoeb for the histopathology evaluations.

**REFERENCES**

The Somatostatin Analog $^{188}$Re-P2045 Inhibits the Growth of AR42J Pancreatic Tumor Xenografts

Carol A. Nelson, Michael T. Azure, Christopher T. Adams and Kurt R. Zinn

J Nucl Med.
Published online: October 30, 2014.
Doi: 10.2967/jnumed.114.140780

This article and updated information are available at:
http://jnm.snmjournals.org/content/early/2014/10/27/jnumed.114.140780

Information about reproducing figures, tables, or other portions of this article can be found online at:
http://jnm.snmjournals.org/site/misc/permission.xhtml

Information about subscriptions to JNM can be found at:
http://jnm.snmjournals.org/site/subscriptions/online.xhtml

JNM ahead of print articles have been peer reviewed and accepted for publication in JNM. They have not been copyedited, nor have they appeared in a print or online issue of the journal. Once the accepted manuscripts appear in the JNM ahead of print area, they will be prepared for print and online publication, which includes copyediting, typesetting, proofreading, and author review. This process may lead to differences between the accepted version of the manuscript and the final, published version.

The Journal of Nuclear Medicine is published monthly.
SNMMI | Society of Nuclear Medicine and Molecular Imaging
1850 Samuel Morse Drive, Reston, VA 20190.
(Print ISSN: 0161-5505, Online ISSN: 2159-662X)

© Copyright 2014 SNMMI; all rights reserved.